Avidity Partners Management »

Aktis Oncology shares owned by Avidity Partners Management

Quarter-by-quarter ownership of Aktis Oncology shares owned by Avidity Partners Management from 13F filings

Historical chart of Avidity Partners Management investment in Aktis Oncology

Tip: Access up to 7 years of quarterly data

All positions including Aktis Oncology held by Avidity Partners Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Aktis Oncology by Avidity Partners Management

Quarter filed Position value Share count Share price at filing
2026-03-31 $8.8M 469k 18.75

More positions owned by Avidity Partners Management

Dianthus Therapeutics (DNTH)
Oruka Therapeutics (ORKA)
Jade Biosciences Com New (JBIO)
Perspective Therapeutics Com New (CATX)
Enliven Therapeutics (ELVN)
Context Therapeutics (CNTX)
Repligen Corporation (RGEN)
Palvella Therapeutics Inc Ne (PVLA)
Aktis Oncology
Medtronic SHS (MDT)
Teva Pharmaceutical Inds Sponsored Ads (TEVA)
Immunic (IMUX)
Vir Biotechnology (VIR)
Dex (DXCM)
Humana (HUM)

View all positions for Avidity Partners Management

Top funds holding Aktis Oncology

MPM Oncology Impact Management
EcoR1 Capital
BlackRock
RA Capital Management
Henderson Group
Baker Bros. Advisors
Octagon Capital Advisors
Merck & Co
Vanguard Capital Management
Geode Capital Management
Avidity Partners Management
AH Capital Management
UBS Group
Arrowpoint Asset Management
Alyeska Investment Group

View all funds holding Aktis Oncology